Breast cancer study tracks real-world outcomes of CDK4/6 inhibitors and next steps after resistance
NCT ID NCT07407439
First seen Feb 13, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This study looks at how well CDK4/6 inhibitors (like palbociclib or abemaciclib) work in real-world settings for people with HR+/HER2- advanced breast cancer. It also explores what treatments doctors choose when the cancer stops responding to these drugs. The goal is to gather information from 245 participants to help guide future treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Tianjin Medical University Cancer Insititute and Hospital
RECRUITINGTianjin, 300060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.